当前位置: X-MOL 学术Virus Evol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection
Virus Evolution ( IF 5.3 ) Pub Date : 2021-06-09 , DOI: 10.1093/ve/veab057
Eric Lewitus 1 , Eric Sanders-Buell 1 , Meera Bose 1 , Anne Marie O'Sullivan 1 , Kultida Poltavee 1 , Yifan Li 1 , Hongjun Bai 1 , Thembi Mdluli 1 , Gina Donofrio 1 , Bonnie Slike 1 , Hong Zhao 2 , Kim Wong 2 , Lennie Chen 2 , Shana Miller 1 , Jenica Lee 1 , Bahar Ahani 1 , Steven Lepore 1 , Sevan Muhammad 1 , Rebecca Grande 1 , Ursula Tran 1 , Vincent Dussupt 1 , Letzibeth Mendez-Rivera 1 , Sorachai Nitayaphan 3 , Jaranit Kaewkungwal 3 , Punnee Pitisuttithum 4 , Supachai Rerks-Ngarm 5 , Robert J O'Connell 3 , Holly Janes 6 , Peter B Gilbert 6 , Robert Gramzinski 1 , Sandhya Vasan 1 , Merlin L Robb 1 , Nelson L Michael 7 , Shelly J Krebs 1 , Joshua T Herbeck 8 , Paul T Edlefsen 6 , James I Mullins 2 , Jerome H Kim 1 , Sodsai Tovanabutra 1 , Morgane Rolland 1
Affiliation  

The scale of the HIV-1 epidemic underscores the need for a vaccine. The multitude of circulating HIV-1 strains together with HIV-1’s high evolvability hints that HIV-1 could adapt to a future vaccine. Here, we wanted to investigate the effect of vaccination on the evolution of the virus post-breakthrough infection. We analyzed 2,635 HIV-1 env sequences sampled up to a year post-diagnosis from 110 vaccine and placebo participants who became infected in the RV144 vaccine efficacy trial. We showed that the Env signature sites that were previously identified to distinguish vaccine and placebo participants were maintained over time. In addition, fewer sites were under diversifying selection in the vaccine group than in the placebo group. These results indicate that HIV-1 would possibly adapt to a vaccine upon its roll-out.

中文翻译:

RV144疫苗印记在突破性感染后限制了HIV-1的进化

HIV-1 流行病的规模凸显了对疫苗的需求。大量循环的 HIV-1 毒株以及 HIV-1 的高进化性暗示 HIV-1 可以适应未来的疫苗。在这里,我们想研究疫苗接种对突破感染后病毒进化的影响。我们分析了 2,635 个 HIV-1 env 序列,从 110 名在 RV144 疫苗效力试验中被感染的疫苗和安慰剂参与者在诊断后一年内取样。我们表明,先前确定的用于区分疫苗和安慰剂参与者的 Env 特征位点随着时间的推移而得以维持。此外,与安慰剂组相比,疫苗组中进行多样化选择的地点更少。这些结果表明,HIV-1 可能会在疫苗推出后适应疫苗。
更新日期:2021-06-09
down
wechat
bug